Health Canada approves Celltrion’s Omlyclo™ (CT-P39), the first and only omalizumab biosimilar in Canada
Celltrion today announced that Health Canada has approved Omlyclo™, a biosimilar referencing Xolair®. Omlyclo™ is approved ...
punjabnewsexpress2d
Celltrion wins approval for allergic asthma treatment biosimilar in Canada
South Korea's pharmaceutical giant Celltrion on Monday said that it has received approval from Canadian health authorities for a biosimilar treatment for allergic asthma.
Celltrion secures Canada's approval for Xolair biosimilar Omlyclo
South Korean biopharmaceutical firm Celltrion said Monday that it has received approval from Health Canada for Omlyclo, its omalizumab biosimilar referencing Xolair, designed to treat allergic asthma ...